| 58.13 -2.6 (-4.28%) | 10-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 88.87 |
1-year : | 101.84 |
| Resists | First : | 76.08 |
Second : | 87.19 |
| Pivot price | 63.52 |
|||
| Supports | First : | 58.11 |
Second : | 48.35 |
| MAs | MA(5) : | 60.76 |
MA(20) : | 64.67 |
| MA(100) : | 78.14 |
MA(250) : | 67.81  |
|
| MACD | MACD : | -4.9 |
Signal : | -4.9 |
| %K %D | K(14,3) : | 12.7 |
D(3) : | 14.8 |
| RSI | RSI(14): 26.3 |
|||
| 52-week | High : | 95.48 | Low : | 36.01 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ARWR ] has closed below the lower bollinger band by 3.4%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 31.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 60.85 - 61.19 | 61.19 - 61.57 |
| Low: | 57.17 - 57.54 | 57.54 - 57.95 |
| Close: | 57.43 - 58.08 | 58.08 - 58.78 |
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
Sun, 11 Oct 2026
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wed, 07 Oct 2026
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Forecasts - Yahoo Finance
Wed, 07 Oct 2026
Arrowhead Pharmaceuticals (NasdaqGS:ARWR) Stock Forecast & Analyst Predictions - Simply Wall Street
Fri, 18 Sep 2026
Arrowhead Pharmaceuticals (ARWR) On ARO DIMER PA Data And Whether Undervaluation Still Holds - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 141 (M) |
| Shares Float | 122 (M) |
| Held by Insiders | 3.6 (%) |
| Held by Institutions | 85.3 (%) |
| Shares Short | 10,760 (K) |
| Shares Short P.Month | 9,430 (K) |
| EPS | -2.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.29 |
| Profit Margin | -47.8 % |
| Operating Margin | -226.1 % |
| Return on Assets (ttm) | -8.2 % |
| Return on Equity (ttm) | -55.3 % |
| Qtrly Rev. Growth | 171 % |
| Gross Profit (p.s.) | 4.73 |
| Sales Per Share | 4.73 |
| EBITDA (p.s.) | -1.43 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -59 (M) |
| Levered Free Cash Flow | -49 (M) |
| PE Ratio | -25.5 |
| PEG Ratio | 0 |
| Price to Book value | 17.61 |
| Price to Sales | 12.26 |
| Price to Cash Flow | -139.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|